GILD : Analysis & Opinions

  • Showing 1-100 of 132 items
  • 1
  • 2
  • >>
  1. High Prescription Drug Prices Draws More Scrutiny

    January 18, 2017
    Two industry leaders suggest that government-run drug companies could limit price hikes.
  2. New and Returning Bio-Tech Stock Picks for 2017

    January 17, 2017
    Biotech stocks had a rough year in 2016, overall. The new year has brought new optimism among some investors, but there are ...
  3. Gilead’s Hepatitis B Drug Vemlidy Approved In EU

    January 12, 2017
    Gilead's hepatitis B drug Vemlidy was approved for marketing in Europe.
  4. Gilead Sciences to Focus on NASH and HIV Drugs

    January 12, 2017
    Gilead will continue to develop NASH and HIV drugs in 2017.
  5. Are M&A Rumors Driving Intercept Pharma's Stock?

    January 5, 2017
    Takeover rumors have fueled huge fluctuations in Intercept Pharmaceuticals shares.
  6. Pharma M&A Boom Expected from 'Trump Tax Holiday'

    January 3, 2017
    Trump's proposed tax holiday may cause a boom in drug mergers, leading to potential job losses.
  7. Generic Version of Roche's Tamiflu Rolls Out in US

    December 12, 2016
    Roche's Tamiflu has competition from a cheaper, generic version of the bestselling flu drug.
  8. Gilead Files New Drug Application for Hep C Combo

    December 9, 2016
    The approval of a single-tablet, three-drug combo could boost Gilead's bottom line.
  9. Hepatitis C Drugs Could Reactivate Hep B (GILD)

    December 5, 2016
    Following last month’s FDA warning, EU regulators have warned that some hepatitis C drugs could reactivate hepatitis B in ...
  10. Gilead Pushes Truvada HIV Prevention Drug (GILD)

    November 30, 2016
    Gilead sees Truvada, the only approved preventive HIV infection therapy in the US, as the next blockbuster drug.
  11. Gilead Launches Phase 3 Crohn's Study (GILD, GLPG)

    November 28, 2016
    Gilead initiated a Phase 3 study for its Crohn's disease drug, giving it an edge over rival AbbVie.
  12. Gilead Dumps GlobeImmune Deal (GILD)

    November 18, 2016
    Gilead's pulled the plug on a drug deal with GlobeImmune, whose stock was delisted.
  13. Gilead Bone Marrow Drug Fails Phase 2 (GILD, INCY)

    November 18, 2016
    Gilead’s momelotinib bone marrow drug failed in two Phase III trials, coming up short against rival Incyte’s Jakafi drug.
  14. These Drugs Led Medicare Spending (GILD, SNY)

    November 15, 2016
    Gilead's hepatitis C drug Harvoni accounted for $7 billion in total spending by Medicare in 2015.
  15. Gilead Hepatitis B Drug Moves Toward EU OK (GILD)

    November 14, 2016
    Gilead's hepatitis B drug moves one step closer to getting European marketing approval.
  16. Gilead's Hepatitis B Drug Vemlidy Approved (GILD)

    November 11, 2016
    The FDA approved Gilead Sciences' hepatitis B drug Vemlidy.
  17. Gilead Pays $200M Milestone for Liver Drug (GILD)

    November 2, 2016
    Gilead Sciences made a $200 million milestone payment to Nimbus Therapeutics for its drug to treat fatty liver disease.
  18. 6 Companies With Exceptional Retirement Plans

    October 27, 2016
    These companies realize that it’s important to take care of their employees not only now but also in the future. Each offers ...
  19. Gilead Hepatitis C Drug Shows Good Results (GILD)

    October 21, 2016
    Gilead's GS-4997 drug showed promising results for hep-C and liver scarring, but failed for pulmonary arterial hypertension ...
  20. Gilead to File NDA for 3-Drug Hep C Combo (GILD)

    October 21, 2016
    Gilead plans to file a new drug application in 4Q 2016 for its three-drug combination to treat hepatitis-C following good ...
  21. Supplemental Indications: The Promising Pharma Stream (GILD)

    October 10, 2016
    While supplemental indications can lead to more revenues and wider treatment options, they may add substantially to the drug ...
  22. High Valuations Hammer Dividend Stocks (AES, EXC)

    October 10, 2016
    Investors have been fleeing dividend stocks with high valuations, but strong opportunities still exist.
  23. Gilead May Lose Sovaldi’s European Patent (GILD)

    October 7, 2016
    More trouble brewing for the company in Europe as its hepatitis C drugs already face declining revenues in the U.S.
  24. Do High Drug Prices Result in Better Stock Returns? (GILD, REGN)

    October 6, 2016
    We examine the past performance of stock returns of companies which have raised the prices of their drugs the most and the ...
  25. FDA Warning Adds to Gilead’s Drug Woes (GILD)

    October 6, 2016
    While nine HCV drugs from five different companies are on the black-box warning list, Gilead's dependence on its HCV portfolio ...
  26. Two Big Biotechs Flash Bearish Signals

    September 30, 2016
    Biotech funds are trading near rally highs, but two popular blue chip components are struggling, a foretelling weakness that ...
  27. Gilead May Not Acquire Galapagos, For Now (GILD, GLPG)

    September 28, 2016
    Though Gilead may not be able to acquire Galapagos at present, the possibility is not ruled out in the near future.
  28. Will Gilead Make a Good Fit for Allergan? (GILD)

    September 22, 2016
    Allergan made two recent acquisitions in the NASH diseases space, and Gilead’s strong NASH drug portfolio can fit well with ...
  29. Gilead Ends Bowel Disease Treatment Trials (GILD)

    September 22, 2016
    Gilead is halting the GS-5745 trials amid insufficient evidence of efficiency for treating ulcerative colitis IBD.
  30. Potential Acquisitions for Gilead Sciences (GILD)

    September 20, 2016
    Gilead’s renewed interest in PARP inhibitor technology for cancer treatment may lead to an acquisition.
  31. Gilead Notes Issue to Close on Sept. 20 (GILD)

    September 16, 2016
    Gilead has priced its $5 billion senior note offering, which offers five different tranches of varying maturity and coupon ...
  32. Most Profitable Health Care Companies of 2016 (GILD, JNJ)

    September 15, 2016
    All four of the most profitable health care companies listed on U.S. exchanges reported net income exceeding $2 billion during ...
  33. Gilead Remains Promising Despite Recent Declines (GILD)

    September 14, 2016
    Though the stock prices have tanked around 24% YTD amid loss of revenues from key drugs, the future looks promising for Gilead’s ...
  34. Omega Drops Stake in Apple, Makes Bet on Citigroup (AAPL, GILD)

    August 16, 2016
    Omega sells off shares in Apple, replacing them with an investment in Citigroup, Netflix and more.
  35. Top 5 Corporate Donors in Big Pharma (GILD, MRK)

    July 29, 2016
    Gilead Sciences, Merck and Pfizer were among the biggest corporate cash donors from the drug and health care sector last ...
  36. Gilead Stock Falls 4% After Guidance Miss (GILD)

    July 25, 2016
    Shares of Gilead are under pressure in the after-hour session Monday after the biotech company issued a fiscal year outlook ...
  37. Political Headwinds Dampen Gilead Sciences Outlook

    July 22, 2016
    Gilead Sciences earnings on July 25 may be overshadowed by Democratic calls to rein in runaway drug pricing.
  38. Gilead Earnings on Tap: Can Hepatitis-C Recover? (GILD)

    July 21, 2016
    Gilead still generates tons of cash to put toward R&D. But with the stock down more than 26% over the past year, are investors ...
  39. Jamie Zimmerman's Q1 Healthcare Stocks: AGN,GILD

    July 12, 2016
    Jamie Zimmerman of Litespeed Managmenet shifts her perspective on healthcare giants AGN and GILD in Q1.
  40. Joel Greenblatt's Biggest Q1 Investment Moves

    July 5, 2016
    Joel Greenblatt, successful hedge fund manager, believes AAPL and GILD have massive growth potential, according to his Q1 ...
  41. Big Biotech Set to Bounce Off Deep Lows (GILD, CELG)

    June 23, 2016
    Relative strength indicators in the biotech sector have hit their deepest oversold readings since 2008, predicting a strong ...
  42. Gilead Stock Trades Ex-Dividend Tuesday (GILD)

    June 14, 2016
    Gilead will send its dividend payment on June 29 to shareholders of record as of June 16.
  43. Gilead Stock Falls on Weak Hepatitis-C Prospects (GILD)

    June 13, 2016
    Analysts at Leerink forecasts revenue for Gilead's hepatitis-C treatment to decline through 2016.
  44. Best Dividend Stocks With Solid Financial Health (AAPL, GILD)

    June 9, 2016
    Learn how Apple, Gilead Sciences and Valero Energy are financially strong, dividend-paying large-cap companies with a potential ...
  45. Breakout Stocks on the Radar (GILD, MMM)

    June 8, 2016
    If these stocks break above short-term resistance they have room to run.
  46. How to Play the Biotech Rally (IBB,GILD,LABD)

    June 3, 2016
    These ETFs and stocks are some of the best bets to play the biotech rebound.
  47. Breaking Down XLV: 3 Components That Are Most Attractive

    May 9, 2016
    Discover three attractive component stocks in the Health Care Select Sector SPDR ETF, and learn which company may be the ...
  48. Gilead Stock: Capital Structure Analysis (GILD)

    May 8, 2016
    Analyze the capital structure of Gilead Sciences to understand the impacts of debt and equity financing. Identify trends ...
  49. Gilead Stock: Analyzing 3 Key Customers (GILD)

    May 5, 2016
    Learn about a handful of important Gilead Sciences customers, including several major pharmaceutical distributors and two ...
  50. Gilead Stock Punished on Q1 Earnings Miss (GILD)

    May 2, 2016
    This was not the quarter investors were gearing up for given the number of price target increases GILD stock enjoyed in the ...
  51. The 3 Largest Alpha-Seeking ETFs (PKW, PDP)

    May 1, 2016
    Learn the tactics of the three largest alpha-seeking ETFs, such as tracking share buybacks and and finding companies with ...
  52. Gilead Stock: Analyzing 5 Key Suppliers (GILD)

    April 29, 2016
    Take a closer look at several key pharmaceutical companies providing Gilead Sciences with important inputs to its pharmaceutical ...
  53. The 3 Largest Health Care ETFs (XLV, IBB)

    April 25, 2016
    Find out which exchange-traded funds (ETFs) are the largest in terms of total assets under management (AUM) in the health ...
  54. 3 Expensive All-Cap ETFs Worth Your While (KNOW, PDP)

    April 21, 2016
    Learn why high expense ratios may not matter when it comes to all-cap ETFs, as well as the funds that have outperformed their ...
  55. Gilead to Provide Healthy Dose of Growth (GILD)

    April 18, 2016
    It's always a good sign when earnings and revenue estimates suggest growth and not a decline.
  56. Gilead's Price Target Raised at Jefferies (GILD)

    April 7, 2016
    Even with the stock's recent rise, GILD stock, which has a consensus buy rating with average analyst price target of $115, ...
  57. Gilead Sciences Rise on Hepatitis C Strength (GILD, MRK)

    April 4, 2016
    Gilead's hepatitis C franchise will prove durable in the face of increased competition, analysts believe.
  58. 3 Best Dividend-Paying U.S. Health Care Mutual Funds (VGHCX, ...

    April 2, 2016
    Find out which mutual funds are paying the highest dividend yields in the health care sector, which has underperformed all ...
  59. Portfolio Trends in 2016 (TRBCX)

    March 25, 2016
    Learn about the portfolio shifts in the T. Rowe Price Blue Chip Growth Fund for 2016 and consider whether the fund is right ...
  60. Portfolio Trends in 2016 (PRHSX)

    March 23, 2016
    Discover how the T. Rowe Price Health Sciences Fund is positioned in 2016, and learn what trends in the portfolio may help ...
  61. (VHT) Vanguard Healthcare ETF: Top 5 Holdings

    March 19, 2016
    Identify the top five holdings in the Vanguard Health Care exchange-traded fund (ETF), and evaluate each holding's business ...
  62. (XLV) Healthcare SPDR ETF: Top 5 Holdings

    March 18, 2016
    Discover the top five stocks in the Health Care Select Sector SPDR Fund, and learn if they can help power your portfolio ...
  63. Has Gilead Sciences Become a Value Stock? (GILD)

    March 18, 2016
    Combined with Gilead's 43-cent per share dividend that yields 1.90% annually, it's tough to not appreciate the attractive ...
  64. (IBB) iShares NASDAQ Biotech SPDR ETF: Top 5 Holdings

    March 16, 2016
    Take a close look at the strong fundamentals underlying the top five holdings of the iShares NASDAQBiotechnology ETF as it ...
  65. Healthcare Sector: Industries Snapshot (XLV, JNJ)

    March 15, 2016
    Discover the six industries that make up the health care sector in the Standard and Poor's 500, and learn which companies ...
  66. How Merck and Daktari Are Working together to Create the HCV ...

    March 12, 2016
    Find out why Merck invested in privately owned Daktari Diagnostics, a company working on a Hepatitis C diagnostics test. ...
  67. 3 Plays for the Biotech Bear Market (GILD, UTHR)

    March 8, 2016
    These short plays should profit from the developing bear market in the biotech sector.
  68. Analyzing Gilead's Return on Equity (GILD, NVO)

    March 7, 2016
    Explore Gilead Science's 2015 return on equity (ROE). Learn about the impact of net margin, asset turnover and financial ...
  69. Gilead's 3 Most Profitable Lines of Business (GILD)

    March 6, 2016
    Discover the top three most profitable products generating over 65% of sales for Gilead Sciences to understand if this stock ...
  70. The 5 Best Performing Stocks in the Last 20 Years (GMCR, CELG)

    February 27, 2016
    Find out which six stocks have performed the best over the past 20 years, which industries generated the most growth and ...
  71. Is Gilead Stock Suitable for Your IRA or Roth IRA? (GLID)

    February 19, 2016
    Learn why Gilead's growing revenues, healthy margins and attractive valuations make it an ideal investment for your traditional ...
  72. 3 Companies With High Working Capital (GT, GILD)

    February 18, 2016
    Learn about working capital, its importance in determining corporate financial stability and three stocks with high working ...
  73. Gilead's 3 Key Financial Ratios (GILD)

    February 13, 2016
    Learn about key financial ratios for Gilead Sciences. Read about a large debt offering the company made in the third quarter ...
  74. Will Gilead's Earnings Be a Shot in the Arm?

    February 1, 2016
    Investors are concerned about the extent to which Gilead's revenue growth, particularly in its hepatitis C business, can ...
  75. Are These the Top Biotech Stocks of 2016?

    January 19, 2016
    These three biotech stocks are likely hold up better than their peers in 2016.
  76. The Top 10 Healthcare Stocks for 2016 (ABT, AGN)

    January 6, 2016
    Learn about the top 10 health care stocks expected to grow in 2016, with brief insights into each company's growth potential ...
  77. The Top 5 Large-Cap Healthcare Stocks for 2016 (GILD, ANTM)

    January 6, 2016
    Learn about the potential direction for large-cap stocks in the health care sector in 2016, drug pricing headwinds and the ...
  78. The Top 10 Large Cap Stocks for 2016 (BCS, AAPL)

    January 5, 2016
    Discover the top 10 large-cap stocks that are expected to grow in 2016, with summaries and individual growth outlooks for ...
  79. The Top 4 Dividend Paying Biotechnology Stocks for 2016 (AMGN, ...

    January 5, 2016
    Discover the top four dividend-bearing biotech stocks for 2016, including one undervalued stock trading at bargain-basement ...
  80. The Top 5 Large Cap Biotechnology Stocks for 2016 (AMGN, BIIB)

    January 5, 2016
    Discover the top five biotechnology stocks for 2016. Learn each company's main revenue drivers and what factors cause their ...
  81. Top 3 NASDAQ-Listed Stocks for 2016 (AAPL, GILD)

    December 23, 2015
    Learn about the top stocks listed on the NASDAQ for 2016. See how Netflix stock has risen dramatically in 2015 and could ...
  82. The World's Top 10 Biotechnology Companies (JNJ, ROG.VX)

    December 22, 2015
    Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational ...
  83. 8 Blue Chip Stocks with Low P/E Ratios

    December 1, 2015
    Discover why the price/earnings (P/E) ratio is important in determining the relative value of a stock and find out which ...
  84. 4 Reasons Gilead Sciences Should be in Your Stock Portfolio (GILD)

    November 30, 2015
    Discover how Gilead Sciences fits into most investment portfolios and learn about the company's drug pipeline and future ...
  85. Gilead Sciences Stock: A Dividend Analysis (GILD)

    October 28, 2015
    Discover analysis of the dividend policy of Gilead Sciences, Inc., and learn about its historical earnings growth and the ...
  86. FDA's Warning Shakes Up Hep C Landscape

    October 23, 2015
    Yesterday, the FDA issued a warning highlighting the risk of potential serious liver injury with Viekira Pak, a drug used ...
  87. The Biggest Risks of Investing in Gilead Stock (GILD)

    September 30, 2015
    Examine the current position of Gilead Sciences, Inc., and learn the major risks for investors considering buying Gilead ...
  88. Key Financial Ratios to Analyze Biotech Companies (AMGN, GILD)

    August 20, 2015
    Explore the rapidly growing biotechnology industry, and learn some of the key financial ratios investors use to analyze companies ...
  89. Top 3 Biotech ETFs (XBI, IBB)

    August 14, 2015
    Learn about three popular ETFs in the biotechnology sector, how they differ, and which ones may be appropriate for long term ...
  90. 3 Value Stocks Millennials Should Consider (COF, GILD)

    August 14, 2015
    Understand what a value stock is and why a value stock would be attractive to a millennial. Learn about three value stocks ...
  91. Celgene Vs. Gilead: Vetting for the Best Biopharma

    August 14, 2015
    Read about the similarities between the drug companies Celgene and Gilead, and learn about promising potential drug candidates ...
  92. 3 Stocks to Protect Your Portfolio From Inflation (CLX, GILD)

    August 13, 2015
    Discover three stocks to protect portfolios against inflation. The best companies to protect against inflation are those ...
  93. How to Create a Personal Risk Management Plan

    July 10, 2015
    Investors should consider these strategies to establish a risk management plan.
  94. What Is the Pharmacy Benefit Management Industry?

    July 2, 2015
    PBMs, acting as third party administrators and negotiators, are essential to facilitating transactions between the moving ...
  95. Could This Patent Decision Be Trouble for Gilead? (GILD)

    June 24, 2015
    When it comes to treating hepatitis C, Gilead Sciences (NASDAQ: GILD) has become a veritable monster. Four years ago, the ...
  96. Are These 3 Biotech Stocks Dirt Cheap? (ABBV, AMAG)

    June 22, 2015
    Everyone loves a bargain, and investors like me are no exception. That's why I like to check in with stocks every quarter ...
  97. Better Dividend Stock: Amgen or Gilead Sciences? (AMGN, GILD)

    June 19, 2015
    Dividend investors don't have very many investing options in the high-flying biotechnology industry, but of those choices, Amgen ...
  98. Why Insider Selling Is a Bad Reason to Sell Gilead (GILD)

    June 15, 2015
    Biotech blue chip stock Gilead Sciences (NASDAQ: GILD) has been nothing short of unstoppable over the past four years. Over ...
  99. Gilead Sciences' Under-the-Radar Growth Machine (GILD)

    June 10, 2015
    It's truly amazing just how quickly Gilead Sciences (NASDAQ: GILD) transformed itself from just another somewhat large biotechnology ...
  100. 10 Developments By Gilead Sciences That Could Boost Profits (GILD)

    June 3, 2015
    Learn about 10 drugs in the pipeline for Gilead Sciences, and learn how it has acquired smaller companies with promising ...
  • Showing 1-100 of 132 items
  • 1
  • 2
  • >>